REG - HealthBeacon PLC HealthBeacon - HBCN - Update on Examinership
01/02/2024 10:45
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240201:nRSA7166Ba&default-theme=true
RNS Number : 7166B HealthBeacon PLC 01 February 2024
Update on Examinership Process
Dublin, 1 February 2024. The board of HealthBeacon plc ("HealthBeacon" or
the "Company) announces an update on the Examinership process the Company is
currently going through.
Further to the announcement made on 31 January 2024, a hearing before the High
Court will take place today at 11.00 am 1 February 2024 seeking the sanction
from the High Court of the Scheme of Arrangement which had been formulated by
the Examiner to enable the Company to survive as a going concern.
The Scheme of Arrangement if approved by the High Court will become binding on
the shareholders and creditors of the Company.
Furthermore, if approved, the interest of the shareholders in the total issued
share capital of the Company will be cancelled. The shareholders shall receive
no distribution on account of their shares and the existing shares and all and
any rights attaching or relating thereto will be cancelled. Any rights and /
or entitlements of the shareholders as members of the Company pursuant to the
articles of association of the Company or any other document, or otherwise,
shall cease if the scheme is approved and admission to trading on Euronext
Growth will be cancelled.
-Ends-
Enquiries: Investor.Relations@HealthBeacon.com
(mailto:Investor.Relations@HealthBeacon.com)
HealthBeacon:
Rebecca Shanahan
Lar Malone
Goodbody (Euronext Listing Sponsor and Broker): +353 (1) 667 0420
Finbarr Griffin
Drury (Public Relations):
Cathal Barry +353 (0) 87 227 9281
Gavin McLoughlin +353 (0) 86 035 3749
About HealthBeacon
Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops smart tools for managing medications for patients in the home.
The HealthBeacon Injection Care Management System tracks adherence and
persistence with medication schedules through the provision of medication
management reminders, safe and sustainable sharps disposal devices,
educational tools, and artificial intelligence (AI) driven data analytics.
Peer reviewed evidence supports a 19% improvement in therapy persistence by
patients and up to 26% improvement in adherence to therapy, which improves
clinical outcomes and significantly improves efficiency in health systems. The
Company has expanded its offering to growth management with the launch of its
integrated Smart Scale and oral adherence with the launch of HB Wave which
integrates with its existing technology. The Company operates across Europe,
North America and the United Kingdom. The Company's mission is to become the
world's leading digital therapeutics platform for patients managing
medications in the home.
End
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END UPDEAEAFEDXLEFA